RxSight Inc (RXST)
58.47
-1.05
(-1.76%)
USD |
NASDAQ |
May 31, 16:00
58.35
-0.12
(-0.21%)
After-Hours: 20:00
RxSight Research and Development Expense (Quarterly): 8.031M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.031M |
| December 31, 2023 | 7.341M |
| September 30, 2023 | 7.101M |
| June 30, 2023 | 7.401M |
| March 31, 2023 | 7.208M |
| December 31, 2022 | 6.681M |
| September 30, 2022 | 6.388M |
| June 30, 2022 | 6.192M |
| March 31, 2022 | 6.719M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.916M |
| September 30, 2021 | 5.377M |
| June 30, 2021 | 6.563M |
| March 31, 2021 | 6.643M |
| December 31, 2020 | 5.272M |
| September 30, 2020 | 5.801M |
| June 30, 2020 | 5.084M |
| March 31, 2020 | 5.777M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.084M
Minimum
Jun 2020
8.031M
Maximum
Mar 2024
6.441M
Average
6.563M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Alphatec Holdings Inc | 18.01M |
| Masimo Corp | 47.80M |
| Tactile Systems Technology Inc | 2.143M |
| iRhythm Technologies Inc | 16.99M |
| Shockwave Medical Inc | 44.47M |